ISSUE 1469
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
The FDA has approved Arnuity Ellipta (GSK), a single-agent inhaler containing the corticosteroid fluticasone furoate, for once-daily maintenance treatment of asthma in patients ≥12 years old. Fluticasone furoate is also available in combination with the long-acting beta2-agonist vilanterol as Breo Ellipta for treatment of asthma and COPD.1
MAINTENANCE TREATMENT — An inhaled corticosteroid is the most effective long-term treatment for control of mild, moderate, or severe persistent asthma. In randomized controlled trials, inhaled corticosteroids have been significantly more effective than long-acting beta2-agonists, leukotriene modifiers, cromolyn, or theophylline in improving pulmonary function, preventing symptoms and exacerbations, reducing the need for emergency department treatment, and decreasing deaths due to asthma.
... more
Would you like to read the rest of this article? Gain access below.
Article code: 1469b
Electronic, downloadable article - $45